Cue Biopharma Files 8-K on Executive and Director Changes
Ticker: CUE · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1645460
Sentiment: neutral
Topics: management-change, corporate-governance
TL;DR
Cue Biopharma 8-K: Board and exec shakeup, details to follow.
AI Summary
On August 28, 2024, Cue Biopharma, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing includes information on the election of directors, appointment of officers, and compensatory arrangements for certain officers, though specific names and dollar amounts related to these changes are not detailed in the provided excerpt.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty about future strategy and execution, warranting closer investor scrutiny.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- August 28, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of incorporation
- 40 Guest Street Boston, Massachusetts 02135 (address) — Principal executive offices
- Imagen Biopharma, Inc. (company) — Former company name
FAQ
What specific changes were made to Cue Biopharma's board of directors?
The filing indicates the election of directors, but the specific names and details of any changes are not provided in this excerpt.
Were there any new appointments of certain officers at Cue Biopharma?
Yes, the filing states the appointment of certain officers as part of the reported events.
Does the filing detail compensatory arrangements for specific officers?
The filing mentions compensatory arrangements of certain officers, but the specific details and amounts are not included in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 28, 2024.
What is Cue Biopharma's former company name?
Cue Biopharma's former company name was Imagen Biopharma, Inc.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-09-03 16:30:09
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
Filing Documents
- cue-20240828.htm (8-K) — 54KB
- 0000950170-24-102851.txt ( ) — 188KB
- cue-20240828.xsd (EX-101.SCH) — 44KB
- cue-20240828_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2024, Michael J. Fox notified Cue Biopharma, Inc. (the "Company") of his decision to resign as a member of the Board of Directors of the Company (the "Board") and all committees thereof, effective on August 28, 2024. Mr. Fox's decision to resign from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: September 3, 2024 By: /s/ Daniel R. Passeri Name: Daniel R. Passeri Title: Chief Executive Officer